It is possible that early in prostate cancer, or upon recurrence, androgen signaling triggers PKR activation and subsequent eIF2α-P, leading to anti-proliferative effects, apoptosis, and the activation of tumor suppressor mechanisms. This evidence concerns the gene EIF2AK2 and prostate carcinoma.